A Study to Examine the Efficacy and Safety of Zanubrutinib Given to Adults With Primary Membranous Nephropathy

← catalyst calendar

NCT05707377 · readout ≤ 437 d

Sponsored by BeOne Medicines (industry) · ONC — their whole pipeline →.

Phase

Phase 2/3

Status

Active, not recruiting

Study type

Interventional

Design

Randomized · None · Treatment

Enrollment

178actual

Sites

Countries

Brazil, Canada, China +6

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2023-04-17

actual

When the study began enrolling

Primary completion

Oct 2027

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

Oct 2027

estimated

The whole study's end, after follow-up

First posted

2023-01-31

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-07-23

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Primary Membranous Nephropathy

Interventions

Drug: Zanubrutinib — also filed as BGB-3111, Brukinsa
Drug: Tacrolimus

Primary outcomes

what the primary-completion date above is the date OF

Part 1: Change from Baseline in Urine Protein Creatinine Ratio (UPCR)

measured Baseline and Week 24

Part 2: Number of Participants Achieving Complete Remission

measured Week 104

Publications

PMID 40465397 — linked by the registry

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · ONC's whole pipeline · Catalyst calendar · Every registered study · What changed